Communications Biology (Nov 2022)
CARD11 mutation and HBZ expression induce lymphoproliferative disease and adult T-cell leukemia/lymphoma
- Takuro Kameda,
- Kotaro Shide,
- Ayako Kamiunten,
- Yasunori Kogure,
- Daisuke Morishita,
- Junji Koya,
- Yuki Tahira,
- Keiichi Akizuki,
- Takako Yokomizo-Nakano,
- Sho Kubota,
- Kosuke Marutsuka,
- Masaaki Sekine,
- Tomonori Hidaka,
- Yoko Kubuki,
- Yuichi Kitai,
- Tadashi Matsuda,
- Akinori Yoda,
- Takayuki Ohshima,
- Midori Sugiyama,
- Goro Sashida,
- Keisuke Kataoka,
- Seishi Ogawa,
- Kazuya Shimoda
Affiliations
- Takuro Kameda
- Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki
- Kotaro Shide
- Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki
- Ayako Kamiunten
- Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki
- Yasunori Kogure
- Division of Molecular Oncology, National Cancer Center Research Institute
- Daisuke Morishita
- Chordia Therapeutics
- Junji Koya
- Division of Molecular Oncology, National Cancer Center Research Institute
- Yuki Tahira
- Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki
- Keiichi Akizuki
- Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki
- Takako Yokomizo-Nakano
- Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences (IRCMS), Kumamoto University
- Sho Kubota
- Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences (IRCMS), Kumamoto University
- Kosuke Marutsuka
- Department of Anatomic Pathology, Miyazaki Prefectural Miyazaki Hospital
- Masaaki Sekine
- Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki
- Tomonori Hidaka
- Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki
- Yoko Kubuki
- Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki
- Yuichi Kitai
- Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University
- Tadashi Matsuda
- Department of Immunology, Graduate School of Pharmaceutical Sciences, Hokkaido University
- Akinori Yoda
- Department of Pathology and Tumor Biology, Kyoto University
- Takayuki Ohshima
- Faculty of Pharmaceutical Sciences at Kagawa Campus, Tokushima Bunri University
- Midori Sugiyama
- Chordia Therapeutics
- Goro Sashida
- Laboratory of Transcriptional Regulation in Leukemogenesis, International Research Center for Medical Sciences (IRCMS), Kumamoto University
- Keisuke Kataoka
- Division of Molecular Oncology, National Cancer Center Research Institute
- Seishi Ogawa
- Department of Pathology and Tumor Biology, Kyoto University
- Kazuya Shimoda
- Division of Hematology, Diabetes, and Endocrinology, Department of Internal Medicine, Faculty of Medicine, University of Miyazaki
- DOI
- https://doi.org/10.1038/s42003-022-04284-x
- Journal volume & issue
-
Vol. 5,
no. 1
pp. 1 – 15
Abstract
The oncogenic ability of mutant CARD11 (E626K), one of most frequently mutated genes in adult T-cell leukemia and its cooperative effect with HBZ expression, using the CD4 promoter-driven HBZ transgenic mouse model, is investigated.
